Razi Vaccine and Serum Research Institute

The Razi Vaccine and Serum Research Institute (romanizated: Mivâssih-e Teheqiqat-e Vaksin-e vâ Sirem-e Sari-ye Razi) is an Iranian pharmaceutical company. It is located in the Hessarak district in Karaj, Iran. The Institute was built as a national center with the purpose of countering epidemics in domestic animals during Reza Shah era. Further departments were installed, including those dedicated to human medicines. In modern years, the Institute has focused primarily on nanomedicine and biotechnology.[1][2]

Razi Vaccine and Serum Research Institute
TypePublic Sector
FoundedKaraj (1924)
FounderMustafa Qoli Bayat
Headquarters
Karaj
,
IRAN
Production output
Human and Animal Medicines
Number of employees
circa 2000
Websitewww.rvsri.ac.ir

The Institute is known for its anti-venom serums derived from snake and scorpion venom. It hosts some reference pharmaceutical laboratories with regional or state scopes.[1][2]

Branches

The Institute has established regional branches in:

History
A technician at the institute inoculating eggs to producing rabies vaccine in 1967.

Production timeline
  • 1924: Institution of the institute.
  • 1932: Louis Delpy, a French veterinarian, drove the institute to overcome an epidemic of cattle plague in the region.
  • 1933: Anthrax
  • 1935: Sheep Pox
  • 1936: Livestock Gangrene
  • 1937: Cattle Pasteurellosis
  • 1941: Serums and vaccines for diphtheria and tetanus
  • 1970: Polio
  • 1987: Rubella and Measles
  • 1998: Aleppo Boil
  • 1992: Foundation of the biotechnology department.
  • 1997: Enhancement of the biotechnology department.
  • 2010: The institute produced 1.7 billion doses of 57 types of vaccines, serums, and antigens per year.
  • 2012: Production of transgenic animals, creating recombinant vaccines through genetic engineering, developing antigens and diagnostic kits for medical and veterinary labs.

Current research projects


History points
  • The facility was used as a Soviet military base during World War II
  • NATO forces used some of the Institute's anti-venom products during the Afghanistan war, since Afghan native snakes had not been researched in the USA or Europe.

See also

References
  1. "Iran | Countries | NTI".
  2. Mahboudi, F; Hamedifar, H; Aghajani, H (2012). "Medical biotechnology trends and achievements in iran". Avicenna Journal of Medical Biotechnology. 4 (4): 200–5. PMC 3558225. PMID 23407888.
  3. Mehdi, Syed Zafar (7 February 2021). "Iran unveils second homegrown COVID-19 vaccine". Anadolu Agency. Retrieved 22 April 2021.
  4. "Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. Retrieved 21 March 2021.
  5. "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. Retrieved 22 April 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.